Cargando…
Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604582/ https://www.ncbi.nlm.nih.gov/pubmed/36295091 http://dx.doi.org/10.3390/life12101657 |
_version_ | 1784817850270089216 |
---|---|
author | Bortoluzzi, Cristiano Bernardi, Enrico Camporese, Giuseppe Noventa, Franco Ceccato, Davide Tonello, Chiara Vo Hong, Ngoc Campello, Elena Simion, Chiara Imbalzano, Egidio Di Micco, Pierpaolo Callegari, Elena Simioni, Paolo |
author_facet | Bortoluzzi, Cristiano Bernardi, Enrico Camporese, Giuseppe Noventa, Franco Ceccato, Davide Tonello, Chiara Vo Hong, Ngoc Campello, Elena Simion, Chiara Imbalzano, Egidio Di Micco, Pierpaolo Callegari, Elena Simioni, Paolo |
author_sort | Bortoluzzi, Cristiano |
collection | PubMed |
description | Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked VTE and a low bleeding risk. Methods: The MAC Project is an ongoing prospective-cohort, multi-center, observational study in Italy. The project aims to collect real-life clinical information in unselected patients given oral anticoagulants for VTE over a 5-year follow-up period. There were no exclusion criteria, except for life expectancy <6 months and refusal to sign the informed consent form or to attend the planned follow-up visit. All patients were followed-up prospectively with clinical controls scheduled at 3, 6, and 12 months after the index event, and then annually for up to 5 years. The primary efficacy and safety outcomes were symptomatic recurrent VTE and major bleeding. Results: We analyzed 450 consecutive patients treated with rivaroxaban and referred them to the MAC Project database for unprovoked or recurrent VTE. Of these, 267 (55%) were unprovoked VTE, and 377 (87%) were symptomatic. We followed up with the patients for a mean of 22 months (Q1 10.7; Q3 37.4 months). Recurrent VTE occurred in 12 patients on rivaroxaban treatment (IR 1.7 per 100 person-years). Males had more recurrence than women. During the follow-up period, we recorded 13 (2.9%) major bleeding, 12 (2.7%) clinically relevant non-major bleeding, 8 minor bleeding, and no fatal bleeding events. Overall, bleeding events occurred in 33 (7.3%) patients, most occurring within the first 2 years of treatment. In addition, we observed a statistically significant higher incidence of bleeding in patients with a baseline HAS-BLED score of 3 to 4 compared with those with a score of 0 to 2, with most events occurring during the first 3 months of treatment (RR 5.9). Discussion: Rivaroxaban appears to be safe and effective for the long-term treatment of patients with recurrent or unprovoked VTE. Our results match previously published data, and we are confident that the continuation of the follow-up for up to 5 years will confirm these outcomes. |
format | Online Article Text |
id | pubmed-9604582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96045822022-10-27 Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project Bortoluzzi, Cristiano Bernardi, Enrico Camporese, Giuseppe Noventa, Franco Ceccato, Davide Tonello, Chiara Vo Hong, Ngoc Campello, Elena Simion, Chiara Imbalzano, Egidio Di Micco, Pierpaolo Callegari, Elena Simioni, Paolo Life (Basel) Communication Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked VTE and a low bleeding risk. Methods: The MAC Project is an ongoing prospective-cohort, multi-center, observational study in Italy. The project aims to collect real-life clinical information in unselected patients given oral anticoagulants for VTE over a 5-year follow-up period. There were no exclusion criteria, except for life expectancy <6 months and refusal to sign the informed consent form or to attend the planned follow-up visit. All patients were followed-up prospectively with clinical controls scheduled at 3, 6, and 12 months after the index event, and then annually for up to 5 years. The primary efficacy and safety outcomes were symptomatic recurrent VTE and major bleeding. Results: We analyzed 450 consecutive patients treated with rivaroxaban and referred them to the MAC Project database for unprovoked or recurrent VTE. Of these, 267 (55%) were unprovoked VTE, and 377 (87%) were symptomatic. We followed up with the patients for a mean of 22 months (Q1 10.7; Q3 37.4 months). Recurrent VTE occurred in 12 patients on rivaroxaban treatment (IR 1.7 per 100 person-years). Males had more recurrence than women. During the follow-up period, we recorded 13 (2.9%) major bleeding, 12 (2.7%) clinically relevant non-major bleeding, 8 minor bleeding, and no fatal bleeding events. Overall, bleeding events occurred in 33 (7.3%) patients, most occurring within the first 2 years of treatment. In addition, we observed a statistically significant higher incidence of bleeding in patients with a baseline HAS-BLED score of 3 to 4 compared with those with a score of 0 to 2, with most events occurring during the first 3 months of treatment (RR 5.9). Discussion: Rivaroxaban appears to be safe and effective for the long-term treatment of patients with recurrent or unprovoked VTE. Our results match previously published data, and we are confident that the continuation of the follow-up for up to 5 years will confirm these outcomes. MDPI 2022-10-20 /pmc/articles/PMC9604582/ /pubmed/36295091 http://dx.doi.org/10.3390/life12101657 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Bortoluzzi, Cristiano Bernardi, Enrico Camporese, Giuseppe Noventa, Franco Ceccato, Davide Tonello, Chiara Vo Hong, Ngoc Campello, Elena Simion, Chiara Imbalzano, Egidio Di Micco, Pierpaolo Callegari, Elena Simioni, Paolo Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title | Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title_full | Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title_fullStr | Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title_full_unstemmed | Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title_short | Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project |
title_sort | safety and efficacy of rivaroxaban for extended-phase anticoagulation of patients with unprovoked or recurrent venous thromboembolism: real-life data from the mac project |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604582/ https://www.ncbi.nlm.nih.gov/pubmed/36295091 http://dx.doi.org/10.3390/life12101657 |
work_keys_str_mv | AT bortoluzzicristiano safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT bernardienrico safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT camporesegiuseppe safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT noventafranco safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT ceccatodavide safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT tonellochiara safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT vohongngoc safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT campelloelena safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT simionchiara safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT imbalzanoegidio safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT dimiccopierpaolo safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT callegarielena safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject AT simionipaolo safetyandefficacyofrivaroxabanforextendedphaseanticoagulationofpatientswithunprovokedorrecurrentvenousthromboembolismreallifedatafromthemacproject |